The success of allogeneic hematopoietic stem cell transplantation from HLA-disparate donors depends on the development of new strategies for graft-versus-host disease prevention able to target specifically donor antihost alloreactivity, while preserving GVL and antiviral immune surveillance. Recent experimental and clinical work has shown the feasibility of an approach based on induction of anergy to host alloantigens through blockade of B7/CD28 costimulatory signal in donor T cells, but data on the impact of this strategy on the recovery of the immune system are still lacking. We devised an ex vivo method for induction of host alloantigen-specific unresponsiveness based on treatment with the B7/CD28 blocking agent CTLA4-Ig associated with CsA. We then proceeded to assess the maintenance of an effective immune response towards viral pathogens and tumor cells after CTLA4-Ig/CsA treatment, by measuring the frequency of CTL precursors directed against CMVand EBV-infected targets, and against autologous leukemic blasts. We demonstrated that (1) CTLA4-Ig and CsA can act synergistically in inducing a state of unresponsiveness to alloantigens; (2) the number of leukemia-reactive, EBV-specific and CMV-specific CTLp is not impaired by CTLA4-Ig/CsA treatment. Our data provide the first direct in vitro evidence that it is possible to preserve antiviral and antileukemia effector cells after blockade of CD28/B7 interaction during MLR. Bone Marrow Transplantation (2001) 27, 1263-1273. Keywords: T lymphocytes; anergy; infectious immunityvirus; tumour immunity; transplantation Allogeneic hematopoietic stem cell transplantation (HSCT) offers the chance of a cure to patients with hematological and immunological disorders. Unfortunately, no more than two-thirds of patients eligible for this procedure have an HLA-matched donor, either related or unrelated. Attempts to augment the size of the donor pool by transplanting unmanipulated hematopoietic progenitors from HLA-haploidentical related or mismatched unrelated donors resulted in a considerable increase in the incidence and severity of GVHD.
HLA-matched donor, either related or unrelated. Attempts to augment the size of the donor pool by transplanting unmanipulated hematopoietic progenitors from HLA-haploidentical related or mismatched unrelated donors resulted in a considerable increase in the incidence and severity of GVHD. 1, 2 The feasibility of HSCT from HLA-haploidentical related or mismatched unrelated donors, achieved through GVHD prevention by means of T cell depletion prior to infusion of stem cells, was first demonstrated in pediatric patients transplanted for primary immunodeficiencies, 3 and more recently confirmed in both adult and pediatric patients given HSCT for malignancy. 4, 5 Notwithstanding the remarkable improvements in the achievement of engraftment without GVHD, infections and leukemia relapse are still a major complication of the delayed immune recovery experienced by patients given T cell-depleted HSCT from HLA-partially matched donors. 4, 5 The development of new approaches to T cell manipulation aimed at selective induction of unresponsiveness [6] [7] [8] [9] [10] or depletion of alloreactive T cells, [11] [12] [13] could allow prevention of GVHD, while drastically reducing the risk of infection and leukemia relapse by accelerating immunological recovery after transplant. This, in turn, could increase the success of these transplants.
Optimal and sustained T cell responses require antigen recognition via T cell receptor (TCR) (first signal) and costimulatory signals delivered through several molecules on the surface of T cells (second signal). 14, 15 It has been demonstrated that lack of costimulation during TCR triggering renders T cells incapable of responding when reexposed to the antigen, a state termed anergy. [16] [17] [18] [19] Several lines of evidence indicate that blockade of the B7/CD28 costimulatory pathway results in Ag-specific T cell anergy. [18] [19] [20] [21] A soluble fusion protein consisting of the extracellular domain of CTLA4, a second counter-receptor for B7 molecules with negative regulatory effects on T cell activation, 22 with the constant region of IgG1 (CTLA4-Ig) shows a high binding affinity with the two B7 family molecules CD80 and CD86, and has, therefore, been extensively employed both in vivo and in vitro as a B7/CD28 blocking agent. 6, [23] [24] [25] [26] [27] A recent clinical trial of HSCT from histoincompatible donors has shown the feasibility of inducing anergy to the recipient alloantigens through ex vivo treatment of donor bone marrow with CTLA4-Ig as a single agent. 28 These preliminary data are of great clinical relevance but, given the fact that a few patients still developed acute GVHD, the approach could probably be further optimized. Moreover, data on reconstitution of specific immunity in these patients are scarce.
Two major concerns regarding T cell anergy induction as a strategy to prevent donor T cell recognition of host alloantigens in the context of HSCT comes from the lack of information on maintenance of immune responses towards widespread pathogens and leukemia cells by tolerized cells, and from the evidence that stimulation of anergic cells with recombinant IL-2 (rIL-2) reverses their state of unresponsiveness. 29, 30 However, it is not completely clear whether at least part of the effect of IL-2 can be ascribed to the expansion of small numbers of Ag-specific T cells that failed to become anergic during primary cultures, 27 and whether a situation comparable to what is observed in vitro in the presence of high concentrations of IL-2 will ever occur in vivo in patients after HSCT.
This study was undertaken for three reasons: (1) to determine whether addition of CsA to an ex vivo method based on the use of CTLA4-Ig as B7/CD28 blocking agent could be additive in inducing host alloantigen specific nonresponsiveness in human donor T cells before allogeneic HSCT; (2) to try to elucidate the respective role of reversal of anergy or expansion of previously unprimed Ag-specific T cells in incomplete prevention of alloreactivity, and to provide a quantification of any residual alloreactive T cells left in the cultures after the in vitro treatment; (3) to assess the maintenance of an effective immune response towards viral pathogens and tumor cells after blockade of CD28/B7 interaction during antigenic stimulation in vitro.
To this end, populations of PBMC, rendered unresponsive towards alloantigens by addition of CTLA4-Ig or a combination of CTLA4-Ig and CsA during a primary MLC in vitro, were prepared, assayed both in bulk culture and limiting dilution conditions, and tested for their residual alloreactive potential and for their immune reactivity against autologous leukemic blasts (LB) and virusinfected cells.
Materials and methods

Isolation of PBMC
Heparinized peripheral blood was obtained from healthy controls or from donor/recipient pairs of HLA-haploidentical bone marrow transplantation. The institutional review board of the Department of Pediatric Sciences, IRCCS Policlinico S Matteo, approved the protocol, and parents gave written informed consent.
PBMC were isolated by Ficoll-Hypaque density gradient centrifugation, and resuspended in RPMI 1640 medium (Gibco, Paisley, UK) supplemented with 2 mm l-glutamine, 50 g/ml gentamicin, and 10% heat-inactivated FCS (Hyclone, Logan, UT, USA) (RPMI-FCS).
Mixed lymphocyte reaction and induction of alloantigenspecific unresponsive cells
To obtain anergic cells, 4 ϫ 10 5 fresh, unstimulated responder PBMC or effector cells induced in a primary MLR were incubated with 4 ϫ 10 5 irradiated (3000 rads) stimulator cells in the presence of CTLA4-Ig (a gift from Dr A Lanzavecchia, Basel Institute of Immunology, Basel, Switzerland), used at a concentration of 2 g/ml, alone or in combination with CsA (purchased from Sandoz Pharmaceuticals, Basel, Switzerland), employed at a concentration of 200 ng/ml in 48-well flat-bottomed plates in 1 ml complete medium. The cells were cultured for 7 days for evaluation in a primary MLR, or, after 5 days culture, cells obtained from single 1-ml wells were harvested, washed, rested for 1-2 days in 48-well plates and then rechallenged in a secondary MLR, or cultured to test the capacity to proliferate in response to polyclonal activators or soluble antigens, and to test the persistence of antileukemia or antiviral immune response. Bulk secondary MLC were obtained by restimulating cells recovered from single primary MLC wells in 48-well plates with thawed stimulators (viability Ͼ80%) at a responder/stimulator ratio of 1:1, with the objective of measuring total residual secondary MLR of a 4 ϫ 10 5 anergic cell dose in comparison with total secondary MLR of the same cell dose of untreated effectors. Proliferation was measured at 3 days, and a 7 day proliferation assay was set up as a control to evaluate any residual activation in primary MLC (lack of activation in primary MLC due to block of both signal 1 and signal 2).
To evaluate proliferative activity, after a 3 day or 7 day incubation at 37°C in a humidified 5% CO 2 Cr-labeled T lymphoblastoid cell lines (T-LCL). T-LCL were obtained by incubating stimulators' PBMC with PHA (M-Form, Gibco) at a concentration of 1:100 v/v and serial passages in complete medium supplemented with rIL-2.
Limiting dilution assay for evaluation of helper T lymphocyte precursors (HTLp)
Thirty replicates of serial two-fold dilutions of responder cells recovered from primary MLC were plated in 96-well, round-bottom microtiter plates in the presence of 3 ϫ 10 4 irradiated stimulator cells in a final volume of 100 l RPMI-FCS. Control wells consisted of irradiated stimulators alone or irradiated responders alone. On day +2 the culture plates were irradiated (25 Gy) to prevent further proliferation of responders, and 1 ϫ 10 3 IL-2-dependent indicator cell line CTLL-2, in 100 l RPMI-FCS were added to each well. The assay was performed as originally described. 32 
Mitogen and antigen proliferation assays
PBL were added in triplicate to U-bottom microwells at a concentration of 0.5 ϫ 10 6 cells/ml. PPD (purified protein derivative of tuberculin) (Serum Institute Copenhagen, Denmark) was added at a concentration of 10 mg/ml, while Tetanus Toxoid (TT) (Inalco, Milan, Italy) was employed at a concentration of 5 g/ml in a final volume of 0.2 ml of RPMI 1640 medium supplemented with 2 mm l-glutamine, 50 g/ml gentamicin and 10% human serum. After a 7 day incubation at 37°C in a humidified 5% CO 2 atmosphere, 3 HTdR incorporation was measured by standard procedure. PHA (M-Form, Gibco) and OKT3 (Ortho, anti-CD3) activation was obtained by incubating PBL in flatbottom microwells with PHA (1:100 v/v) and OKT3 mAb (5 ng/ml) respectively, for 3 days.
Production of EBV-induced B lymphoblastoid cell line (B-LCL)
PBMC were incubated with EBV-containing supernatant from the B95.8 cell line (American Type Culture Collection, Rockville, MD, USA) in the presence of 800 ng/ml of CsA in RPMI-FCS. Cells were continuously incubated at 37°C, 5% CO 2 for 3-4 weeks, following a protocol previously described. 33 
Limiting dilution assay for evaluation of CMV-and EBVspecific CTLp
To evaluate CTLp frequency to CMV-infected fibroblasts, fresh PBMC or cells recovered from primary MLC were Bone Marrow Transplantation seeded in a final volume of 200 l in 96-well round-bottom microplates. Autologous fibroblasts were infected with AD169 strain CMV following a previously described method. 34 Decreasing numbers of responder cells (10 4 , 5 ϫ 10 3 , 2.5 ϫ 10 3 , 1.25 ϫ 10 3 , 0.6 ϫ 10 3 ) were stimulated with 2 ϫ 10 3 autologous infected fibroblasts. When cells recovered from primary MLC were used as responders, 4 ϫ 10 4 irradiated (3000 rads) PBMC were added as feeder cells. On day 4 and 9, 40 U/ml rIL-2 were added to the cultures. On day 12, the cultures were split and tested against CMV-infected and mock-infected fibroblasts.
For evaluation of EBV-specific CTLp, responder cells were stimulated with autologous irradiated B-LCL following a previously described method. 35 4 irradiated PBMC were added as feeder cells. On day 5 and 10, 40 U/ml rIL-2 were added to the cultures. On day 15, the cultures were split and tested against autologous or HLA-mismatched B-LCL.
Limiting dilution assay for evaluation of leukemiareactive CTLp
The persistence of antileukemia activity after induction of alloantigen-specific unresponsiveness was evaluated by means of a limiting dilution assay, as previously reported. ) were seeded together with 2 ϫ 10 4 irradiated LB (7000 rads), in 96-well round-bottom microplates. When MLC effectors were used as responders, 2 ϫ 10 4 irradiated autologous PBMC were added to the cultures as feeder cells. Control wells contained irradiated autologous LB without responder cells. Cultures were maintained in complete medium supplemented with 100 U/ml of rIL-2 (Hoffman-La Roche), and incubated at 37°C in 5% CO 2 . On day 10, wells were accurately resuspended and 100 l of each well transferred for split experiments. Cultures were then tested for cytolytic activity against LB, autologous bone marrow cells collected at time of hematological remission (BMRC), and allogeneic T-LCL.
Cytotoxicity assay
Cytotoxic activity was measured as previously described. 31 Spontaneous release from the target cells was consistently less than 25%. Results were expressed as % specific lysis.
Calculation of CTLp frequency
Assay wells were defined as positive when 51 Cr release exceeded the average plus 3 s.d. of control wells. The fre-quency of responding cells was determined by maximum likelihood estimation using a statistical program and the variance by the use of 95% confidence limits.
Results
CTLA4-Ig combined with CsA induces a state of unresponsiveness to alloantigens
In a series of 10 experiments employing PBMC from nine different donors and their haploidentical bone marrow transplant recipients, we analyzed the effect of treatment with the B7-blocking agent CTLA4-Ig, in the presence or in the absence of CsA, on primary MLR culture (Table 1) . After a 5 day incubation, cells were recovered, washed, rested for 1-2 days, and then restimulated with recipients' PBMC in secondary cultures without further addition of blocking agents. Unresponsiveness was arbitrarily defined as a proliferative response upon rechallenge that was Ͻ10% of the primary untreated MLR. In experiments using PBMC from eight of nine donors, treatment with CTLA4-Ig alone during primary in vitro stimulation was sufficient to induce effective unresponsiveness to alloantigen. In one donor (donor G), however, CTLA4-Ig alone did not succeed in rendering T cells alloantigen-unresponsive (Table 1 ; mean residual response of the 10 experiments in primary MLR: 1.9% ± 1.3; mean residual response in secondary MLR: 3.4% ± 5.1). In all donors tested, the combination of CTLA4-Ig and CsA was highly effective in inducing unresponsiveness to alloantigen (mean residual response of the 10 experiments in primary MLR: 0.6% ± 0.5; mean residual response in secondary MLR: 1.8% ± 1.9). Proliferation of 7 day secondary MLR in treated cultures was comparable or lower than that observed at 3 days. Cell recovery after treated primary MLR ranged between 35 and 80% (mean recovery: 45%) of control MLR.
To demonstrate that addition of CsA to the treatment with CTLA4-Ig at the doses employed in our protocol, did not totally prevent alloantigen recognition, we analyzed the kinetics of expression of activation molecules during cul- PBMC (0.5 × 10 6 /ml) from nine donors (A-I) were stimulated with HLA-haploidentical cells (0.5 × 10 6 /ml), in the presence or in the absence of CTLA4-Ig (2 g/ml) or the combination of CTLA4-Ig (2 g/ml) and CsA (200 ng/ml). Subsequently, the cells were rested and rechallenged with the same stimulators in the absence of blocking agents. Results are expressed as mean thymidine incorporation of triplicate wells.
ture. In untreated MLC, the % of CD25 + , HLA-DR + , and CD69 + T cells gradually increased to reach peak values on days 6-7. In treated cultures, an early activation was observed, testified by an initial increase of CD69
+ (see Figure 1) and HLA-DR + cells, but it was not followed by the subsequent expansion of populations expressing these activation molecules, as found in untreated cultures. In contrast to results of control MLC, the % of CD25
+ lymphocytes remained at baseline values throughout the culture period.
Unresponsive T cells induced by the combination of CTLA4-Ig and CsA, or by CTLA4-Ig alone, may display residual alloreactivity when rechallenged in limiting dilution conditions
With the aim of providing quantification of residual alloreactivity possibly left in the cultures after treatment with CTLA4-Ig and CsA, and not detectable in bulk culture conditions, we evaluated secondary MLR between HLA class I and class II-mismatched donors in limiting dilution assays, in the presence of low doses of rIL-2 (5 U/ml). Treatment of primary MLR with CTLA4-Ig and CsA resulted in a 1-2.5 log inhibition of PTLp and CTLp frequency, measured in secondary MLR, in all pairs tested (Figure 2, panels a and c) . To determine the antigen-specificity of the unresponsiveness, primary MLR effectors were also challenged with third party stimulators that were HLAmismatched with responders and stimulators. As shown in Figure 2b and d, the ability of the cells to proliferate after third-party stimulation was preserved.
We then proceeded to compare the effect of treatment with CTLA4-Ig and CsA vs CTLA4-Ig alone on secondary PTLp, CTLp and HTLp assays. Again, a consistent reduction of PTLp and CTLp was observed with both treatment modalities (Figure 3) , although the inhibition caused by combination treatment was more marked than that obtained with CTLA4-Ig alone. The effect of incubation with CTLA4-Ig and CsA or with CTLA4-Ig alone on HTLp were comparable, a 1.5 log decrease in cytokine-producing T cell precursors having been observed in both treatment Bone Marrow Transplantation conditions ( Figure 3 ). In order to ascertain whether unresponsiveness was due to functional inactivity, or to clonal deletion of responsive cells, we tested whether unresponsiveness would be reversible upon serial rechallenges with the Ag in the presence of high doses of rIL-2. The data in Figure 3 show that multiple rechallenges in the absence of rIL-2 failed to reverse unresponsiveness. On the other hand, restimulation with Ag and 100 U/ml rIL-2 restored allospecific proliferation and cytotoxicity in three out of four experiments performed, while unresponsiveness was maintained in one case (Figure 4 ).
Unresponsive T cells induced by the combination of CTLA4-Ig and CsA maintain the capacity to proliferate to nominal antigens and to develop virus-specific cytotoxic activity
In order to employ this model of alloreactive T cell modulation in the context of T cell-depleted, mismatched HSCT, it is crucial to demonstrate that treated T cells retain their other immunological functions. We therefore verified whether unresponsive T cells could still proliferate in response to polyclonal activators or nominal antigens, and kill virus-infected targets. Cells treated with CTLA4-Ig and CsA for 5 days were able to proliferate against PHA, candida, tetanus toxoid and PPD (data not shown). Moreover, when challenged with virus-infected stimulators in limiting dilution assays, unresponsive T cells maintained a high frequency of EBV-specific and CMV-specific CTLp ( Figure  5 ).
Induction of allospecific unresponsiveness by the combination of CTLA4-Ig and CsA does not impair cytolytic activity of leukemia-reactive effector cells
An important factor influencing success in T cell-depleted HSCT for leukemia is the possibility of preventing relapse through immunological control of the malignant clone. To assess the persistence of leukemia-directed cytotoxic T cells, alloantigen unresponsiveness was induced in PBMC of two patients affected by acute myeloid leukemia, and given autologous HSCT in one case and HSCT from a syngeneic donor in the other, by treatment with CTLA4-Ig and CsA in the presence of parental stimulators. The choice of tolerizing patients' cells, and not donors' lymphocytes, was due to the fact that LB-reactive CTLp frequency is mostly undetectable in the peripheral blood of HSCT donors with the method described, 37 due to the presence of a very low number of specific precursors. By contrast, both patients selected for our experiments showed a high frequency of these precursors after autologous or syngeneic transplant. Cytolytic activity, measured as frequency of CTLp directed towards patient pretransplant LB, was then evaluated in a 10-day limiting dilution assay, using patients untreated PBMC, effector cells of untreated and CTLA4Ig/CsAtreated MLC as responders, and autologous LB as stimulators. Cytotoxicity was tested against patients' LB, patients' BMRC or T-LCL, and parental T-LCL.
Data reported in Figure 6 show that anergic T cells retained the capacity to lyse efficiently pretransplant LB, their CTLp frequency being higher than baseline LB- 
Figure 4
Effect of addition of rIL-2 to secondary MLR cultures on maintenance of alloantigen-specific unresponsiveness. CTLA4-Ig and CsA were added to the MLR cultures for 5 days (primary MLR, 1 o MLR). Cells were then rested, rechallenged with the same stimulators in the absence of blocking agents, and in the presence or in the absence of rIL-2 (100 U/ml) for 3 days or 7 days, and the proliferative response upon rechallenge was determined (secondary MLR, 2 o MLR). For tertiary cultures (3 o MLR), secondary MLR cells were recovered on day 3, rested and rechallenged for 3 days. Data show proliferation of untreated () and treated MLR (í). Unchallenged PBMC were used as a control for primary MLR, while secondary or tertiary culture control was represented by anergic cells cultured in the absence of stimulators (a). Results of two separate experiments out of four performed are reported, expressed as the mean c.p.m./min obtained from triplicate cultures. s.e.m.s were Ͻ10%.
reactive CTLp frequencies observed in the PBMC of the two patients after HSCT. In both patients, anergic T cells did not lyse autologous bone marrow remission cells, and more importantly, an undetectable frequency of CTLp against the original HLA-haploidentical stimulator T cells was shown by treated effectors. In one patient (patient 2), the effectors were also tested against patient's T-LCL, and the CTLp frequency obtained was undetectable (data not shown).
Discussion
In this report, we describe the feasibility of inducing alloantigen-specific long-term unresponsiveness in human PBMC as a result of blocking costimulatory interactions by means of ex vivo treatment with CTLA4-Ig and CsA during primary MLR stimulation. We found that the two agents may have an additive effect in preventing alloreactivity. In fact, while in most pairs tested B7/CD28 costimulatory pathway blockade with CTLA4-Ig was sufficient to obtain alloantigen-specific unresponsiveness, addition of CsA was necessary in a few cases to shift from hyporesponsiveness to complete inhibition of allo-specific responses. 10, 27 The choice of CsA for the combination treatment derived from Bone Marrow Transplantation previous experience reported by van Gool et al 8 and recently confirmed in a model of anergy induction in human memory T cells by Yi Qun et al 27 based on the observation that this agent blocks calcium-dependent intracellular signal transduction pathways, and it is likely to affect costimulatory signals other than CD28. Our data are apparently in contrast with reports 6, 16, 38 describing an inhibitory effect of CsA on anergy induction. As already pointed out by Yi Qun et al, the reasons for these discrepancies may lie with both the kind of APC used to induce anergy, and the variable CsA concentrations employed in the different activation models reported. In our model, the unmanipulated APC used as stimulators, together with the relatively low doses of CsA associated with CTLA4-Ig, did not completely prevent the delivery of the first signal after MHC/TCR interaction. The partial T cell activation, also testified by the phenotype pattern of the anergic cells, was sufficient to induce anergy in the responsive T cells. Likewise, differences between animal and human models, and the complexity of the in vivo scenario of tolerance induction, may account for the negative effect of CsA on graft acceptance recently reported by Larsen et al. 39 The alloreactivity observed, residual potential alloreactive precursors may be present in the final culture product after ex vivo treatment with CTLA4-Ig, alone or in combination with CsA, even when undetectable in bulk cultures. The residual alloreactivity observed in the majority of experiments performed could be due to reversal of unresponsiveness, or to outgrowth of T cells with low affinity for the host histocompatibility antigen which thus escaped the induction of functional inactivity. Limiting dilution and bulk culture experiments performed in the presence of rIL-2 have shown that, when detectable, residual alloreactivity is seen after a 7 day rechallenge, rather than after the standard 3 day secondary MLC. These data support the hypothesis of late activation of T cell subsets with low TCR affinity, even though a contribution from reversal of anergy cannot be completely excluded.
The few T cells that escape induction of anergy in vitro might still expand in vivo through cytokine stimulation under certain unfavorable conditions, such as excess of antigen and abundance of APCs, and cause lethal or lifethreatening GVHD, as confirmed by clinical evidence obtained both in animal models, 25, 26 and in the first recent report on ex vivo CTLA4-Ig treatment of donor bone marrow for histoincompatible transplantation. 28 In this regard, viral and bacterial infections have been documented to play a role in breaking peripheral T cell tolerance, 40, 41 and there is a possibility that in the case of EBV reactivation after transfer of tolerized T cells, cross-reactive memory T cells might restore the alloresponse to common human leukocyte antigens.
The residual alloreactivity observed in these cases, that may translate into an increased risk of developing GVHD once donor T cells be transferred to the recipient, could be limited by favoring a transfer protocol of escalating doses of unresponsive T cells after a classic T cell-depleted HSCT, rather than treatment of the bulk stem cell inoculum prior to transplantation.
A central problem of pursuing the prevention of GVHD in histoincompatible HSCT through selective depletion or inhibition of donor anti-host alloreactivity concerns the impact of the strategy employed on global cell recovery and on maintenance of antiviral immune surveillance and graft-versus-leukemia (GVL).
A few data obtained in primates immunized after in vivo CTLA4-Ig administration 42 suggested the possibility that this treatment could induce suppression of T cell-dependent immune responses. However, results reported by Blazar et al 26 have shown that combined in vivo and ex vivo blockade of costimulatory pathways by anti-LFA-1 and CTLA4-Ig is not associated with augmented immunosuppression in the mouse. In keeping with this latter study, our results indicate that ex vivo treatment of donor PBMCs stimulated in MLR against host alloantigens with CTLA4-Ig and CsA does not result in a high degree of cell death, and more importantly, that proliferation to third-party alloantigens, as well as to nominal antigen challenges remains substantially unmodified after the tolerization process. There was a theoretical concern that functional inhibition of alloreactivity could affect immune responses to viral antigens, as it is generally agreed that there is cross-reactivity between memory T cells specific for viruses, such as EBV, and foreign MHC. In the present study, we demonstrate that EBV-specific and CMV-specific cytotoxic activity is not impaired by CTLA4-Ig/CsA treatment.
The persistence of antileukemia activity after inducing host-specific alloantigen unresponsiveness is crucial for successful allogeneic HSCT in patients with malignancy. A number of clinical and experimental observations indicate that adoptively transferred donor lymphocytes are involved in both GVHD and GVL activity, but there is also mounting evidence that there can be a GVL reaction not strictly associated with GVHD. 12 In our study, we proceeded to assess the persistence of antileukemia CTLs after in vitro treatment with CTLA4-Ig and CsA, designing the experiment in an autologous/syngeneic setting, to be able to dissect leukemia-directed cytotoxic activity independent of alloantigen recognition. We demonstrate that a high frequency of precursors able to kill autologous leukemia cells, comparable to that observed in the untreated PBMC of the same patient after autologous or syngeneic transplant, is spared after manipulation of costimulatory signals. Since it is probable that, for the intrinsic nature of the proposed treatment, part or all of the GVL effect connected to alloreactivity will be hampered by anergy induction, the finding that CTLA4-Ig and CsA do not impair antileukemia activity independent of alloreactivity is of relevant clinical interest. Clearly, the hypothesis that the allo-independent phenomenon depicted by our leukemia-reactive CTLp assay might have a role on in vivo eradication or immune control of Bone Marrow Transplantation residual clonogenic tumor cells remains to be proven in clinical studies.
In summary, we conclude that the present model of modulation of costimulatory signals through combined in vitro CTLA4-Ig/CsA treatment, is effective for induction of allo-specific unresponsiveness in donor T cells. Moreover, our data provide the first direct in vitro evidence that it is possible to preserve antiviral and antileukemia effector cells after blockade of CD28/B7 interaction during antigenic stimulation in vitro. The efficacy of the strategy described in accelerating immune reconstitution in vivo, with minimal risk of developing GVHD, needs to be evaluated in a phase I clinical trial with post-transplant add-back of controlled numbers of tolerized donor T cells after T cell-depleted HSCT.
